Summary
The partial dopamine receptor agonists SDZ 208-911 {N-[(8-alpha)-2,6-dimethylergoline-8-yl]-2,2-dimethylpropanamide|, and terguride (transdihydrolisuride; TDHL) were tested in biochemical, behavioral (locomotor activity) and electrophysiological assays in male rats. In reserpine-pretreated rats, SDZ 208-911 and terguride dose-dependently reduced striatal DOPA formation (NSD 1015 treatment) with similar efficacy (−80%) and potency as the selective D2 receptor agonist quinpirole (LY 171555). SDZ 208-912 only produced a partial reduction (−32%) at the highest dose tested. SDZ 208-911 and terguride partially reversed (by approximately 50%) the gamma-butyrolactone (GBL)-induced increase in striatal DOPA accumulation. Quinpirole produced a 100% reversal while SDZ 208–912, per se, was inactive. While quinpirole decreased DOPA accumulation, all three partial agonists elevated striatal DOPA accumulation in non-pretreated rats with SDZ 208–912 being as potent and efficacious as haloperidol. The three partial agonists displayed comparatively high affinities in vitro for the dopamine D2 (3H-spiperone) receptor site and somewhat lower affinity for the 5-HT1A (3H-8-OH-DPAT) receptor site. SDZ 208–911 and SDZ 208–912 also showed high affinities for central alpha2 (3H-idazoxane) receptors. In line with these findings, the partial ergoline agonists dose-dependently elevated the DOPA accumulation in the noradrenaline-rich cortical brain region and decreased the 5-HT synthesis rate (5-HTP accumulation) in the limbic brain region. Furthermore, high doses of SDZ 208–911 and terguride produced weak signs of the 5-HT behavioral syndrome (flat body posture) in reserpinized rats. In the locomotor activity studies in non-pretreated rats, SDZ 208–911, SDZ 208-912 and terguride reduced the activity to 10–20% of controls with SDZ 208–912 being approximately ten times less potent than the other two compounds. Weak postsynaptic dopamine receptor agonist effects of the partial agonists were demonstrated only in reserpine-pretreated rats; all three partial agonists tested produced occasional forward locomotion and the so-called “jerking” behavior. Extracellular single unit recordings were carried out in chloral hydrate-anesthetized rats to investigate the effects on firing rates of dopamine neurons located in the substantia nigra pars compacta. Intravenous administration of SDZ 208–911 and terguride depressed the firing rate by 42 and 53%, respectively, while apomorphine completely inhibited the cells. SDZ 208–912 only reduced the firing by 16% and some cells displayed a biphasic response with a weak depression at low doses that disappeared at high doses. SDZ 208–912 and SDZ 208–911 completely reversed the inhibition of firing rate produced by d-amphetamine, while SDZ 208–912 partially (81 %) reversed the inhibitory effects of apomorphine. It is concluded that all three amino-ergolines possess partial dopamine receptor agonistic effects with SDZ 208–911 and terguride displaying a similar intrinsic efficacy (in certain models approximately 50% of that of quinpirole or apomorphine). On the other hand, SDZ 208–912 displays a very low intrinsic efficacy, detectable only in the electrophysiological model and in reserpinized rats. The results are discussed in relation to the potential clinical utility of these compounds as antipsychotic agents.
Similar content being viewed by others
References
Aghajanian GK, Bunney BS (1977) Dopamine “autoreceptors”: Pharmacological characterization by microiontophoretic single cell recording studies. Naunyn-Schmiedeberg's Arch Pharmacol 297:1–7
And'en N-E, Grabowska M (1976) Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons. Eur J Pharmacol 39:275–282
Andén N-E, Grabowska-Andén M (1990) B-HT920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors. J Neural Transm 79:209–214
Andén N-E, Golembiowska-Nikitin K, Thornström U (1982) Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn-Schmiedeberg's Arch Pharmacol 32:100–104
Arnt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60:205–223
Arvidsson L-E, Hacksell U, Nilsson JLG, Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikström H (1981) 8-Hydroxy-2(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem 24:921–923
Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560–570
Carlsson A (1978) The mechanism of action of neuroleptic drugs. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: A generation of progress. Raven Press, New York, pp 1057–1070
Carlsson A (1983) Dopamine receptor agonists: Intrinsic activity vs. state of the receptor. J Neural Transm 57:309–315
Carlsson M, Eriksson E (1988) The intrinsic activity of (−)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion. Life Sci 42:585–588
Carlsson A, Lindqvist M (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437–440
Carlsson A, Kehr W, Lindqvist M (1977) Agonist-antagonist interaction on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation. J Neural Transm 40:99–113
Clark D, Hjorth S, Carlsson A (1985a) Dopamine receptor agonists: Mechanism underlying autoreceptor selectivity. I Review of the evidence. J Neural Transm 62:1–52
Clark D, Hjorth S, Carlsson A (1985b) Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II Theoretical considerations. J Neural Transm 62:171–207
Clark D, Hjorth S, Carlsson A (1985c) (+)- and (−)-3-PPP exhibit different intrinsic activity at striatal dopamine synthesis. Eur J Pharmacol 106:185–189
Clark D, Engberg G, Pileblad E, Svensson TH, Carlsson A, Freeman AS, Bunney BS (1985d) An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system. Naunyn-Schmiedeberg's Arch Pharmacol 329:344–354
Coward DM, Dixon AK, Urwyler S, Vigouret J-M (1988) Pharmacological properties of SDZ 208–912: A potential high potency, non-classical neuroleptic. Pharmacopsychiatry 21:312–313
Coward DM, Dixon AK, Urwyler S, White TG, Enz A, Karobath M, Shearman G (1990) Partial dopamine-agonistic and atypical neuroleptic properties of the amino ergolines SDZ 208–911 and SDZ 208–912. J Pharmacol Exp Ther 252:279–285
Drukarch B, Stoof JC (1990) D-2 dopamine autoreceptor selective drugs: Do they really exist? (Minireview) Life Sci 47:361–376
Elliott PJ, Walsh DM, Close SP, Higgins GA, Hayes AG (1990) Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology 29:949–956
Engström G, Svensson TH, Waldeck B (1974) Thyroxin and brain catecholamines: increased transmitter synthesis and increased receptor sensitivity. Brain Res 77:471–483
Eriksson E, Modigh K, Carlsson A, Wikström H (1983) Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. Eur J Pharmacol 96:29–36
Exner M, Furmidge LJ, White FJ, Clark D (1989) Inhibitory effects of partial D2 dopamine receptor agonists on the d-amphetamine cue. Behav Pharmacol 1:101–111
Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptor activation. Neurology 33:1489–1492
Grabowska-Anden M, Anden N-E (1983) Stimulation of postsynaptic DA2 receptors produce jerks in reserpine-treated rats. J Pharm Pharmacol 35:543–545
Hjorth S, Carlsson A (1987) Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist S K&F 38393. Psychopharmacology 93:534–537
Hjorth S, Svensson K, Carlsson A, Wikström H, Andersson B (1986) Central dopaminergic properties of HW 165 and its enantiomers; Trans-octahydrobenzo(f)quinoline congeners of 3-PPP. Naunyn-Schmiedeberg's Arch Pharmacol 333:205–218
Hjorth S, Clark D, Carlsson A (1988) Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Eur J Pharmacol 152:207–215
Hoffmann WE, Piercey MF (1987) Depression of dopamine neuron firing rates by the selective dopamine autoreceptor agonists, (−)-3-PPP and (−)-HW165. Soc Neurosci Abstr 13:908
Hyttel J, Arnt J (1987) Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions. J Neural Transm 68:171–189
Karobath M, Coward D, Enz A, Haefliger W, Jaton A, Markstein R, Palacios JM, Shearman G, Supavilai P, Wiederhold KH, Vigouret J-M (1988) Functional effects of partial D2 dopamine receptor agonists. In: Progress in catecholamine research. Part B: Central Aspects. Dahlström A, Belmaker HR, Sandler M (eds) Neurology and Neurobiology: Alan R. Liss, New York. vol 42A, pp 19–26
Kehr W (1984) Transdihydrolisuride, a partial dopamine receptor antagonist: Effects on monoamine metabolism. Eur J Pharmacol 97:111–119
Martin GE, Pettibone DJ (1985) Dopamine agonist activity of EMD 23,488. J Neural Transm 61:115–123
Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology 82:409–410
Naber D, Macher J-P, Gerlach J, Kasas A, Moeglen J-M, Bailey P (1990) SDZ HDC-A novel atypical antipsychotic agent: A four week multicenter open therapeutic trial in Schizophrenia. Abstract, 17th CINP meeting, Kyoto, Japan
Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21:389–390
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates (2nd Ed). Academic, Sydney, pp 119
Piercey MF, Hoffmann WE, Vogelsang GD, Travis M (1987) Electrophysiological evaluation of a partial agonist of dopamine receptors. J Pharmacol Exp Ther 243:391–396
Piercey MF, Broderick PA, Hoffmann WE, Vogelsang GD (1990) U-66444B and U-68553B, potent autoreceptor agonists at dopaminergic cell bodies and terminals. J Pharmacol Exp Ther 254:369–374
Seyfried CA, Fuxe K, Wolf HP, Agnati AF (1983) Neurochemical and functional studies with EMD 23,448, a novel dopamine agonist. Acta Pharm Suec Suppl 2:243–248
Shum A, Sole AJ, van Loon GR (1982) Simultaneous measurement of 5-hydroxytryptophan and 1-dihydroxyphenylalanine by high performance liquid chromatography with electrochemical detection. Measurement of serotonin and catecholamine turnover in discrete brain regions. J Chromatogr 228:123–130
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151
Svensson K (1986) Dopamine autoreceptor antagonists: A new class of central stimulants. PhD Thesis, ISBN 91-7900-078-9
Svensson K, Johansson AM, Magnusson T, Carlsson A (1986) (+)-AJ76 and (+)-UH232: Central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 334:234–245
Wadenberg ML, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic like effects without catalepsy. J Neural Transm 83:43–53
Walters JR, Roth RH (1976) Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 274:5–14
Winckler P, Bartels M (1990) Selective presynaptic dopamine agonist treatment of schizophrenia with B-HT920. Abstract, International Symposium on presynaptic receptors and neuronal transporters (Satellite meeting to IUPHAR, 1990) June 26–29, Rouen, France
Author information
Authors and Affiliations
Additional information
Send offprint requests to K. Svensson at the above address
Rights and permissions
About this article
Cite this article
Svensson, K., Ekman, A., Piercey, M.F. et al. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 344, 263–274 (1991). https://doi.org/10.1007/BF00182999
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00182999